{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T20:00:01Z","timestamp":1722110401793},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The purpose of this study was to investigate the correlation of bone marrow edema (BME) in sacroiliac joint (SIJ) with clinical characteristics and clinical response, and whether the quick decrease of BME could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis (AS) patients.<\/jats:p>\n            <jats:p>Ninety active AS patients underwent etanercept treatment for 6 months were enrolled consecutively and classified into standard dose group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a37) and dose tapering group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u200a=\u200a53). BME in SIJ and clinical response were assessed by SPARCC criteria and ASAS 40 response criteria, respectively. \u201cQuick decrease of BME in SIJ\u201d was defined as the decrease of SPARCC score\u226550% from M0 to M1.<\/jats:p>\n            <jats:p>BME in SIJ was positively correlated with pain VAS score, BASDAI score, CRP, IL-1\u03b2, IL-17, and TNF-\u03b1 levels. ASAS 40 response rate at M6 was lower in dose tapering group than standard dose group, while higher in patients with a quick decrease of BME in SIJ than other patients. Besides, the ASAS 40 response rate in dose tapering group was similar to standard dose group in patients with a quick decrease of BME in SIJ but was lower than standard dose group in patients without a quick decrease of BME in SIJ at M6.<\/jats:p>\n            <jats:p>A quick decrease of BME in SIJ predicts better treatment response to etanercept, and it might be served as a novel marker for dose tapering initiation of etanercept in AS patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014620","type":"journal-article","created":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T11:46:07Z","timestamp":1552823167000},"page":"e14620","source":"Crossref","is-referenced-by-count":6,"title":["A quick decrease of bone marrow edema in sacroiliac joint could be served as a novel marker for dose tapering of etanercept in ankylosing spondylitis patients"],"prefix":"10.1097","volume":"98","author":[{"given":"Ruishan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of CT\/MRI, The Second People's Hospital of Liaocheng, Linqing, Shandong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongda","family":"Liu","sequence":"additional","affiliation":[{"name":"Foot and Ankle Surgery, The Second Hospital of Tangshan, Tangshan, Hebei"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengpo","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, The Second People's Hospital of Liaocheng, Linqing, Shandong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1002\/jcp.26500","article-title":"MicroRNA implications in the etiopathogenesis of ankylosing spondylitis","author":"Mohammadi","year":"2018","journal-title":"J Cell Physiol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biopha.2018.01.108","article-title":"Immune cells involved in the pathogenesis of ankylosing spondylitis","volume":"100","author":"Rezaiemanesh","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00296-016-3452-0","article-title":"Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern\/Central Europe, Latin America, and Asia","volume":"36","author":"Damjanov","year":"2016","journal-title":"Rheumatol Int"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11926-013-0344-0","article-title":"Ankylosing spondylitis: Chinese perspective, clinical phenotypes, and associated extra-articular systemic features","volume":"15","author":"Ho","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/rheumatology\/ker083","article-title":"High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)","volume":"50","author":"Navarro-Sarabia","year":"2011","journal-title":"Rheumatology"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12895-016-0048-z","article-title":"A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50\u200amg twice weekly followed by etanercept 25\u200amg twice weekly, the combination of etanercept 25\u200amg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Dermatol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/03009742.2017.1330419","article-title":"Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab","volume":"47","author":"Ruwaard","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50\u200amg once-weekly and 25\u200amg twice-weekly","volume":"46","author":"Braun","year":"2007","journal-title":"Rheumatology"},{"issue":"(suppl 2)","key":"R11-20230914","first-page":"272","article-title":"THU0211 low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis: retrospective cohort study","volume":"74","author":"Park","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Compan","year":"2011","journal-title":"Clinical Rheumatol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00296-011-1920-0","article-title":"The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis: a case series","volume":"32","author":"Moghimi","year":"2012","journal-title":"Rheumatol Int"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0394632016656013","article-title":"Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population","volume":"29","author":"Li","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25\u200amg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin Rheumatol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25\u200amg once weekly as effective as 50\u200amg at maintaining response in patients with ankylosing spondylitis? a randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","volume":"33","author":"De Stefano","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.semarthrit.2008.01.005","article-title":"Bone marrow edema in the cervical spine of symptomatic rheumatoid arthritis patients","volume":"38","author":"Narv\u00e1ez","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4081\/reumatismo.2014.790","article-title":"A clinical overview of bone marrow edema","volume":"66","author":"Manara","year":"2014","journal-title":"Reumatismo"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/rheumatology\/kep427","article-title":"The evidence for whole-spine MRI in the assessment of axial spondyloarthropathy","volume":"49","author":"Bennett","year":"2010","journal-title":"Rheumatology"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","article-title":"MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis","volume":"67","author":"Rudwaleit","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"57","DOI":"10.12659\/PJR.883768","article-title":"Significance of bone marrow edema in pathogenesis of rheumatoid arthritis","volume":"78","author":"Kwiatkowska","year":"2013","journal-title":"Pol J Radiol"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.2009.04383.x","article-title":"Bone marrow edema","volume":"1154","author":"Schett","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/med-2016-0011","article-title":"DWI and SPARCC scoring assess curative effect of early ankylosing spondylitis","volume":"11","author":"Qin","year":"2016","journal-title":"Open Med"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.20790","article-title":"Assessment in Ankylosing Spondylitis International Working Group\/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24024","article-title":"Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years","volume":"58","author":"Bennett","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbspin.2006.03.010","article-title":"25\u200amg etanercept once weekly in rheumatoid arthritis and spondylarthropathy","volume":"74","author":"Berthelot","year":"2007","journal-title":"Joint, bone, spine: revue du rhumatisme"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2147\/PPA.S33109","article-title":"Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis","volume":"7","author":"Senabre-Gallego","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"R31-20230914","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14712598.2014.868433","article-title":"Clinical and economic impact of the use of etanercept 25\u200amg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients","volume":"14","author":"Borras-Blasco","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903150-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:47:48Z","timestamp":1694728068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903150-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014620","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}